ADAMTSL1

Across TCGA pan-cancer cohorts, ADAMTSL1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADAMTSL1 data layer compared with 18 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ADAMTSL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAMTSL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where ADAMTSL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.860	.003	19	view →
HNSC	OS	Median	IV	0.899	0.619	.004	16	view →
LSCC	OS	Tertile	II,III,IV	0.937	0.769	.020	14	view →
LUAD	OS	Quartile	All	0.716	0.925	.019	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADAMTSL1–CCRCC (DFS)

Open the CCRCC breakdown →